Clinical Research Directory
Browse clinical research sites, groups, and studies.
Nicorandil in Atherosclerosis Risk in Patients With Rheumatoid Arthritis
Sponsor: Tanta University
Summary
The goal of this clinical trial is to learn about the effects of adding nicorandil to conventional Disease-Modifying Antirheumatic Drugs(DMARDs) in treatment of patients with rheumatoid arthritis. The main questions it aims to answer are: Does adding nicorandil to conventional DMARDs in treatment of patients with rheumatoid arthritis reduce the risk of plaque buildup in arteries (atherosclerosis) ? and What medical problems may participants have when taking nicorandil ? Participants will: Take nicorandil added to DMARDs or DMARDs only for 3 months patient will be assessed at baseline and 3 months after for disease activity and risk of plaque formation over vascular wall Keep a diary of their symptoms and possible side effects
Official title: Effect of Nicorandil on Atherosclerosis Risk in Patients With Rheumatoid Arthritis: A Randomized Controlled Clinical Trial.
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2026-09
Completion Date
2027-04
Last Updated
2026-09-02
Healthy Volunteers
No
Conditions
Interventions
Nicorandil 10 MG Oral scored Tablet
Nicorandil 5 mg oral (half of scored tablet 10 mg) taken twice daily before meals added on csDMARD for 3 months.
DMARD maintenance
used as control group
Locations (1)
Rheumatology, Rehabilitation and Physical Medicine department -Tanta university hospitals
Tanta, Gharbia Governorate, Egypt